• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Standard BioTools Inc.

    11/14/24 3:32:10 PM ET
    $LAB
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $LAB alert in real time by email
    SC 13G/A 1 form_sc13ga-standard.htm

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934
    (Amendment No. 5)*
     
    Standard BioTools Inc.
    (Name of Issuer)

    Common Stock, par value $0.001 per share
     (Title of Class of Securities)

    34385P108
    (CUSIP Number)
     
     
    September 30, 2024
    (Date of Event Which Requires Filing of this Statement)
     
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
     
     
     
     
     
    ☒
    Rule 13d-1(b)
     
    ☐
    Rule 13d-1(c)
     
    ☐
    Rule 13d-1(d)
     
    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosure provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
     



    CUSIP No. 34385P108
     
    SCHEDULE 13G
           
     
    1
    NAME OF REPORTING PERSONS.
     
    Indaba Capital Management, L.P.
     
     
    2
    Check the Appropriate Box if a Member of a Group (See Instructions)
     
    (a) [   ]
    (b) [X]
     
     3
    SEC Use Only
      
     
    4
    Citizenship or Place of Organization
     
    Delaware
     
     
     
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY
    OWNED BY EACH REPORTING
    PERSON WITH
     
     
     
    5
     
    Sole Voting Power
     
    0
     
     
     
    6
     
     
    Shared Voting Power
     
    2,641,379 (1)
     
     
     
    7
     
    Sole Dispositive Power
     
    0
     
     
     
    8
     
    Shared Dispositive Power
     
    2,641,379 (1)
     
     
     
    9
     
    Aggregate Amount Beneficially Owned by Each Reporting Person
     
    2,641,379 (1)
     
     
    10
     
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [   ]
      
     
    11
     
    Percent of Class Represented by Amount in Row (9)
     
    0.7% (1)(2)
     
     
    12
     
    Type of Reporting Person (See Instructions)
     
    IA, PN
     

    (1) Amount reported includes 2,641,379 shares of common stock of Standard BioTools Inc. (the “Issuer”) issuable upon conversion of the Issuer’s 5.25% Convertible Senior Notes due 2024 (the “Notes”). 

    (2) Based on 371,154,471 shares of the Issuer’s common stock outstanding as of August 2, 2024, as disclosed in the Issuer’s Form 10-Q filed with the Securities and Exchange Commission (“SEC”) on August 6, 2024.

    CUSIP No. 34385P108
     
    SCHEDULE 13G
           
     
    1
    NAME OF REPORTING PERSONS.
     
    IC GP, LLC
     
     
    2
    Check the Appropriate Box if a Member of a Group (See Instructions)
     
    (a) [   ]
    (b) [X]
     
     3
    SEC Use Only
      
     
    4
    Citizenship or Place of Organization
     
    Delaware
     
     
     
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY
    OWNED BY EACH REPORTING
    PERSON WITH
     
     
     
    5
     
    Sole Voting Power
     
    0
     
     
     
    6
     
     
    Shared Voting Power
     
    2,641,379 (1)
     
     
     
    7
     
    Sole Dispositive Power
     
    0
     
     
     
    8
     
    Shared Dispositive Power
     
    2,641,379 (1)
     
     
     
    9
     
    Aggregate Amount Beneficially Owned by Each Reporting Person
     
    2,641,379 (1)
     
     
    10
     
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [   ]
      
     
    11
     
    Percent of Class Represented by Amount in Row (9)
     
    0.7% (1)(2)
     
     
    12
     
    Type of Reporting Person (See Instructions)
     
    OO, HC
     

    (1) Amount reported includes 2,641,379 shares of the Issuer’s common stock issuable upon conversion of the Notes. 

    (2) Based on 371,154,471 shares of the Issuer’s common stock outstanding as of August 2, 2024, as disclosed in the Issuer’s Form 10-Q filed with the SEC on August 6, 2024.



    CUSIP No. 34385P108
     
    SCHEDULE 13G
           
     
    1
    NAME OF REPORTING PERSONS.
     
    Derek C. Schrier
     
     
    2
    Check the Appropriate Box if a Member of a Group (See Instructions)
     
    (a) [   ]
    (b) [X]
     
     3
    SEC Use Only
      
     
    4
    Citizenship or Place of Organization
     
    Delaware
     
     
     
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY
    OWNED BY EACH REPORTING
    PERSON WITH
     
     
     
    5
     
    Sole Voting Power
     
    0
     
     
     
    6
     
     
    Shared Voting Power
     
    2,641,379 (1)
     
     
     
    7
     
    Sole Dispositive Power
     
    0
     
     
     
    8
     
    Shared Dispositive Power
     
    2,641,379 (1)
     
     
     
    9
     
    Aggregate Amount Beneficially Owned by Each Reporting Person
     
    2,641,379 (1)
     
     
    10
     
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [   ]
      
     
    11
     
    Percent of Class Represented by Amount in Row (9)
     
    0.7% (1)(2)
     
     
    12
     
    Type of Reporting Person (See Instructions)
     
    IN, HC
     

    (1) Amount reported includes 2,641,379 shares of the Issuer’s common stock issuable upon conversion of the Notes.

    (2) Based on 371,154,471 shares of the Issuer’s common stock outstanding as of August 2, 2024, as disclosed in the Issuer’s Form 10-Q filed with the SEC on August 6, 2024.


    Amendment No. 5 to Schedule 13G

     Item 1.
     
     
     
     
     
     
     
     
     
     
     
    (a)
    Name of Issuer
     
     
     
     
    Standard BioTools Inc. (the “Issuer”)
     
     
     
     
    (b)
    Address of Issuer’s Principal Executive Offices
     
     
     
    2 Tower Place, Suite 2000, South San Francisco, CA 94080
     
    Item 2.
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
    (a)
    Name of Person Filing
     
     
     
     
    This Schedule 13G is being filed jointly on behalf of:
     
    (i) Indaba Capital Management, L.P., a Delaware limited partnership (the "Investment Manager"),
     
    (ii) IC GP, LLC, a Delaware limited liability company, and the Investment Manager’s sole general partner (“IC GP”), and
     
    (iii) Derek C. Schrier, a United States citizen and the Managing Member of IC GP (the “Managing Member” and, collectively with the Investment Manager and IC GP, the “Reporting Persons”).
     
     
     
    (b)
    Address of Principal Business office or, if None, Residence
     
     
     
    The business address of each of the Reporting Persons is One Letterman Drive, Building D, Suite DM700, San Francisco, California 94129.
     
     
     
    (c)
    Citizenship:
     
     
     
     
    The Investment Manager is a Delaware limited partnership, IC GP is a Delaware limited liability company and the Managing Member is a United States citizen.
     
     
     
    (d)
    Title of Class Securities:
     
     
     
     
    Common Stock, par value $0.001 per share (“Common Stock”)
     
     
     
    (e)
    CUSIP Number:
     
     
     
     
    34385P108
     
     
     

     
     
    Item 3.
    If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:

     
     
     
    (a) [  ] Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78c);
     
     
     
    (b) [  ] Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);
     
     
     
    (c) [  ] Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);
     
     
     
    (d) [  ] Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8);
     
     
     
    (e) [X] An investment adviser in accordance with 240.13d-1(b)(1)(ii)(E);
     
     
     
    (f)  [  ] An employee benefit plan or endowment fund in accordance with 240.13d-1(b)(1)(ii)(F);
     
     
     
    (g) [X] A parent holding company or control person in accordance with 240.13d-1(b)(1)(ii)(G);
     
     
     
    (h) [  ] A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
     
     
     
    (i)  [  ] A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
     
     
     
    (j)  [  ] A non-U.S. institution in accordance with 240.13d-1(b)(1)(ii)(J);
     
     
     
    (k) [  ] Group, in accordance with 240.13d-1(b)(1)(ii)(K).
     

    Item 4.
    Ownership
     
    (a) Amount beneficially owned:
     
    As of September 30, 2024, the Reporting Persons beneficially owned the shares of Common Stock referenced in Item 9 of the cover page pertaining to each Reporting Person and such Item 9 disclosure is incorporated herein by reference.

    The shares of Common Stock beneficially owned by the Reporting Persons are directly held by Indaba Capital Fund, L.P. (the “Fund”), a private investment fund for which the Investment Manager serves as investment manager.  Pursuant to an Investment Management Agreement, the Fund and its general partner have delegated all voting and investment power over the shares of Common Stock directly held by the Fund to the Investment Manager.
      
    (b) Percent of class:
     
    Incorporated by reference to Item 11 of the cover page pertaining to each Reporting Person.

    (c) Number of shares to which the person has:
     
     
    (i) Sole power to vote or to direct the vote:
     
     
    Incorporated by reference to Item 5 of the cover page pertaining to each Reporting Person.
     
     
    (ii) Shared power to direct the vote:
     
     
    Incorporated by reference to Item 6 of the cover page pertaining to each Reporting Person.
     
     
    (iii) Sole power to dispose or to direct the disposition of:
     
     
    Incorporated by reference to Item 7 of the cover page pertaining to each Reporting Person.
     
     
    (iv) Shared power to dispose or to direct the disposition of:
     
     
    Incorporated by reference to Item 8 of the cover page pertaining to each Reporting Person.
     
     

    Item 5.
    Ownership of Five Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class securities, check the following [X].
     
     
    Item 6.
    Ownership of More than Five Percent on Behalf of Another Person.

    Not applicable.   
     
    Item 7.
    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

    Not applicable.
     
    Item 8.
    Identification and Classification of Members of the Group.
     
    Not applicable.
     
     
    Item 9.
     
    Notice of Dissolution of Group.

    Not applicable.
     
    Item 10.
      Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
     

    SIGNATURE
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date:  November 14, 2024
     
     
    INDABA CAPITAL MANAGEMENT, L.P.
     
     
     
     
     
    By:
     IC GP, LLC, its general partner
     
     
     
     
     
     
    By:
     /s/ Derek C. Schrier
     
     
     
    Name: Derek C. Schrier
     
     
     
    Title: Managing Member
     
     
     
     
     
     
    IC GP, LLC
     
     
     
     
     
     
    By:
     /s/ Derek C. Schrier
     
     
     
    Name: Derek C. Schrier
     
     
     
    Title: Managing Member
     
     
     
     
     
     
     
     
     
     
    /s/ Derek C. Schrier 
     
     
    DEREK C. SCHRIER 
     
      
     
    Get the next $LAB alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $LAB

    DatePrice TargetRatingAnalyst
    2/27/2025Overweight → Sector Weight
    KeyBanc Capital Markets
    4/16/2024$3.50Buy
    TD Cowen
    4/4/2024$3.25Buy
    Jefferies
    7/12/2023$4.00Overweight
    KeyBanc Capital Markets
    More analyst ratings

    $LAB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Standard BioTools downgraded by KeyBanc Capital Markets

      KeyBanc Capital Markets downgraded Standard BioTools from Overweight to Sector Weight

      2/27/25 6:22:46 AM ET
      $LAB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • TD Cowen initiated coverage on Standard BioTools with a new price target

      TD Cowen initiated coverage of Standard BioTools with a rating of Buy and set a new price target of $3.50

      4/16/24 8:09:43 AM ET
      $LAB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Jefferies initiated coverage on Standard BioTools with a new price target

      Jefferies initiated coverage of Standard BioTools with a rating of Buy and set a new price target of $3.25

      4/4/24 7:41:52 AM ET
      $LAB
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $LAB
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Illumina to acquire SomaLogic, accelerating its proteomics business and advancing the company's multiomics strategy

      Combines highly complementary proteomics expertise with Illumina's industry-leading product innovation and global market reach Positions Illumina to achieve growth in a large, expanding market Illumina and SomaLogic have partnered in proteomics co-development since late 2021 SAN DIEGO, June 23, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) announced today it has entered into a definitive agreement with Standard BioTools (NASDAQ:LAB) under which Illumina will acquire SomaLogic, a leader in data-driven proteomics technology, and other specified assets for $350 million in cash payable at closing, subject to customary adjustments, plus up to $75 million in near-term performance-based milesto

      6/23/25 7:13:00 AM ET
      $ILMN
      $LAB
      Medical Specialities
      Health Care
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Standard BioTools Enters Next Phase of Transformation with Strategic Sale of SomaLogic to Illumina

      Up To $425 Million In Total Proceeds Inclusive of Near-term Milestone Payments; $350 Million In Upfront Cash   Retains Strategic Upside with Illumina Protein Prep Royalty Stream and Rights to Single SOMAmer Reagent Business   Simplifies Operating Structure and Enables Achievement of Adjusted EBITDA Break-Even    Cash & Cash Equivalents of At Least $550 Million Expected at Close to Fuel Inorganic Growth Strategy and Drive Long-Term Value Creation SOUTH SAN FRANCISCO, Calif., June 23, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ:LAB) (the "Company" or "Standard BioTools") today announced the strategic sale of SomaLogic to Illumina, Inc. (NASDAQ:ILMN) ("Illumina"), including Soma

      6/23/25 7:05:18 AM ET
      $ILMN
      $LAB
      Medical Specialities
      Health Care
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Standard BioTools to Host Inaugural "Proteomics Roundtable" Webcast Series

      SOUTH SAN FRANCISCO, Calif., May 30, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ:LAB) today announced the launch of its inaugural Proteomics Roundtable Series – a program of virtual events designed to spark conversation about the rapidly evolving field of proteomics. The series will spotlight thought leaders and industry experts discussing groundbreaking research, technological advancements and real-world applications of proteomics shaping the future of healthcare. The first session will be: Is More Really More? Evaluating the Case for High-Plex, High-Quality ProteomicsFriday, June 6, 2025 – 11:00 am ET Stephen Williams, MD, PhD, Chief Medical Officer at Standard BioTools wi

      5/30/25 7:00:00 AM ET
      $LAB
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $LAB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Casdin Partners Master Fund, L.P. disposed of $580,425 worth of shares (545,000 units at $1.06), was granted 58,215 shares, bought $5,134,321 worth of shares (4,820,959 units at $1.06) and acquired $580,425 worth of shares (545,000 units at $1.06) (SEC Form 4)

      4 - STANDARD BIOTOOLS INC. (0001162194) (Issuer)

      3/4/25 8:19:51 PM ET
      $LAB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Director Casdin Partners Master Fund, L.P. bought $546,750 worth of shares (250,000 units at $2.19) (SEC Form 4)

      4 - STANDARD BIOTOOLS INC. (0001162194) (Issuer)

      8/29/24 8:30:41 PM ET
      $LAB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Director Casdin Partners Master Fund, L.P. bought $1,546,237 worth of shares (750,000 units at $2.06) (SEC Form 4)

      4 - STANDARD BIOTOOLS INC. (0001162194) (Issuer)

      8/26/24 8:10:10 PM ET
      $LAB
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $LAB
    SEC Filings

    See more
    • Standard BioTools Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - STANDARD BIOTOOLS INC. (0001162194) (Filer)

      6/23/25 9:11:17 AM ET
      $LAB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Standard BioTools Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - STANDARD BIOTOOLS INC. (0001162194) (Filer)

      6/20/25 4:16:03 PM ET
      $LAB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SD filed by Standard BioTools Inc.

      SD - STANDARD BIOTOOLS INC. (0001162194) (Filer)

      6/2/25 4:06:54 PM ET
      $LAB
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $LAB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Cox Troy was granted 94,592 shares, increasing direct ownership by 58% to 256,412 units (SEC Form 4)

      4 - STANDARD BIOTOOLS INC. (0001162194) (Issuer)

      6/24/25 7:00:22 PM ET
      $LAB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Director Eloi Fenel M was granted 94,592 shares, increasing direct ownership by 67% to 236,183 units (SEC Form 4)

      4 - STANDARD BIOTOOLS INC. (0001162194) (Issuer)

      6/24/25 6:58:52 PM ET
      $LAB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Director Carey Thomas D. was granted 94,592 shares, increasing direct ownership by 95% to 194,058 units (SEC Form 4)

      4 - STANDARD BIOTOOLS INC. (0001162194) (Issuer)

      6/24/25 6:58:06 PM ET
      $LAB
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $LAB
    Leadership Updates

    Live Leadership Updates

    See more
    • Standard BioTools Appoints Alex Kim as Chief Financial Officer

      SOUTH SAN FRANCISCO, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. ("Standard BioTools" or the "Company") (NASDAQ:LAB) today announced the appointment of Alex Kim as Chief Financial Officer, effective November 11, 2024. Kim, a co-founder and most recently Chief Operating Officer of Standard BioTools, brings nearly 30 years of financial and operations experience in the healthcare and life sciences industries to the role and will oversee Standard BioTools' finance organization. Michael Egholm, President and Chief Executive Officer of Standard BioTools, said, "I am thrilled to announce Alex as our next CFO. Having co-founded Standard BioTools with me, Alex's deep understan

      11/7/24 8:00:00 AM ET
      $LAB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Madryn Asset Management, a Top Shareholder of SomaLogic, Issues Letter Regarding Opposition to the Company's Proposed Merger with Standard BioTools

      Files Preliminary Proxy Statement to Solicit Shareholders to Oppose the Merger Intends to Vote AGAINST the Conflict-Plagued and Excessively Dilutive Transaction, Which Stands to Unduly Benefit Certain Investors and Standard BioTools at the Expense of SomaLogic's Shareholders Notes the Current Premium for SomaLogic Shareholders, Based on the Deal's Exchange Ratio and Standard BioTools' Trading Price, is Only ~4.3% Underscores That SomaLogic Has Superior Alternatives to a Flawed Combination, Including a Standalone Path Leveraging its Considerable Cash Position and Strong Balance Sheet Madryn Asset Management, LP (collectively with its affiliates, "Madryn"), a holder of approximately 4

      12/12/23 5:31:00 PM ET
      $EXAS
      $ILMN
      $LAB
      $ME
      Medical Specialities
      Health Care
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Standard BioTools Appoints Jeffrey Black as Chief Financial Officer and Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

      Industry veteran Jeffrey Black brings 30 years of financial and operating leadership experience Vikram Jog to become Special Advisor for transition period SOUTH SAN FRANCISCO, Calif., May 15, 2023 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health – announced the appointment of Jeffrey Black as Senior Vice President and Chief Financial Officer effective today. Black will lead Standard BioTools' finance, accounting and investor relations functions, reporting to Michael Egholm, Ph.D., President and Chief Executive Officer. Vikram Jog will remain at the company for a period as Special Advisor to th

      5/15/23 7:30:14 AM ET
      $LAB
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $LAB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Standard BioTools Inc.

      SC 13G/A - STANDARD BIOTOOLS INC. (0001162194) (Subject)

      11/14/24 3:32:10 PM ET
      $LAB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Amendment: SEC Form SC 13G/A filed by Standard BioTools Inc.

      SC 13G/A - STANDARD BIOTOOLS INC. (0001162194) (Subject)

      11/12/24 6:01:47 PM ET
      $LAB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Amendment: SEC Form SC 13G/A filed by Standard BioTools Inc.

      SC 13G/A - STANDARD BIOTOOLS INC. (0001162194) (Subject)

      11/4/24 1:59:57 PM ET
      $LAB
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $LAB
    Financials

    Live finance-specific insights

    See more
    • Standard BioTools Reports First Quarter 2025 Financial Results

      SOUTH SAN FRANCISCO, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ:LAB) (the "Company" or "Standard BioTools") today announced financial results for the first quarter ended March 31, 2025. Recent Highlights: First quarter 2025 revenue of $40.8 million45% reduction in operating loss and 29% improvement in adjusted EBITDA year-over-yearOperationalized $10 million more in annual run rate cost reductions, totaling $90 million since merger Strong balance sheet with $261 million in cash & cash equivalents and no material debt as of March 31, 2025 "Standard BioTools delivered a solid first quarter in line with our expectations, reflecting focused execution in a

      5/6/25 4:01:00 PM ET
      $LAB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Standard BioTools Schedules First Quarter Earnings Conference Call on May 6, 2025

      SOUTH SAN FRANCISCO, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ:LAB) today announced that it will report first quarter 2025 financial results on Tuesday, May 6, 2025, after market close. The company will host a conference call and webcast on the same day at 4:30 p.m. ET to discuss its financial results and operational progress. Individuals can access the conference call by dialing: US domestic callers: (888) 346-3970Outside US callers: (412) 902-4297 Live audio of the webcast will be available online on the Investor Relations page of the Company's website at Events & Presentations. The webcast will be archived and available on Standard BioTools™ Investor R

      4/22/25 7:00:00 AM ET
      $LAB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Standard BioTools Reports Fourth Quarter and Full Year 2024 Financial Results

      SOUTH SAN FRANCISCO, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ:LAB) (the "Company" or "Standard BioTools") today announced financial results for the fourth quarter and fiscal year ended December 31, 2024. Recent Highlights: Full Year 2024 pro forma combined revenue of $175.1 million17% Full Year reduction in pro forma operating loss and 33% year over year improvement in adjusted EBITDA Additional $10 million in operational cost reductions, now totaling $90 million in synergies over 12 monthsStrong Balance sheet with $295 million in cash, cash equivalents, restricted cash, short-term investments and no material debt at year end 2024 expected to provide suffi

      2/26/25 4:01:00 PM ET
      $LAB
      Biotechnology: Laboratory Analytical Instruments
      Industrials